Thursday, April 3, 2025
Home Tags Ctxr

Tag: ctxr

Citius, Leonard Mazur
2020 Watch List

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

Editor / Curator -
Citius
Biotech News

Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise...

Editor / Curator -
Citius, Biotech Stock Review
2020 Watch List

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

Editor / Curator -
Biotech News

Make Hay While the Sun Shines. Up 6,400%.

Editor / Curator -
Stem Cells

Heads Up! Big News on Stem Cells & Covid This Weekend.

Editor / Curator -
cITIUS
2020 Watch List

Citius (CTXR) Announces Results of Mino-Lok Study.

Editor / Curator -
Issam Radd
2020 Watch List

Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

Editor / Curator -
Interview

Citius Pharma (CTXR) Video Presentation.

Editor / Curator -
citius pharma, biotech stock review
2020 Watch List

Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in...

Editor / Curator -
Biotech News

Where is Citius Pharma (CTXR) in the FDA Approval Process?

Editor / Curator -
1234Page 2 of 4

Latest article

Bavarian Nordic (BVNRY) Freeze Dries its MPOX Vaccine!

2025 Watch List Editor / Curator -
This is Big News, Honestly. We Are Adding to 2025 Watch List @ $7.36. We last added Bavarian to...

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.’s ‘Misinformation And Lies’ (IBD)

All News Editor / Curator -
Sorting Through the Wreckage! Full post on Investor's Business Daily. Biotech stocks took a beating Monday...

Zomedica (ZOMDF) Surges 40% Higher, Friday.

All News Editor / Curator -
Stock Surges 40%, After Management Conference Call to Calm the Natives. Insider Buying Unleashed Today? Not...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.